系统性红斑狼疮患者DNA甲基化状态与趋化因子受体表达水平的研究
摘要
目的
探讨系统性红斑狼疮(SLE)患者中p16基因启动子甲基化状态及其在发病机制中的作用。
方法
检测45例SLE患者血浆DNA甲基化状态、72例SLE患者全血细胞DNA甲基化状态，并以20名健康对照者血浆和全血细胞作为对照。应用甲基化特异PCR(MSP)方法检测p16基因启动子区甲基化状态，其原理为：DNA经亚硫酸氢钠修饰后，p16基因启动子区含CpG区域可以用PCR进行扩增。对扩增结果与患者疾病活动性、临床表现及常规实验室检查结果之间的关联进行分析。
结果
1、SLE患者血浆DNA中p16基因启动子呈现高甲基化状态：
(1)SLE组中p16基因启动子呈甲基化状态者占64.44％(29／45)，而健康对照组中只有1名检测到p16基因甲基化(1／20，5％)，两组间差异具有统计学意义(X~2=19.687~b，p＜0.001；OR=34.44；95％CI[19.25～49.63])。活动期SLE组p16基因呈甲基化状态者所占比率83.33％(20／24)比非活动期SLE组42.85％(9／21)高，差异也有明显统计学意义(x~2=8.008~b；P=0.005，＜0.01；OR=6.67)。
(2)初发SLE组p16基因启动子呈甲基化状态者所占比例(71.43％，15／21)，与复发SLE组(58.33％)相比差异没有统计学意义(p=0.371)。
Objectives:
To investigate the state of p16 gene DNA methylation in plasma from the patients with Systemic Lupus Erythematosus (SLE) and its clinical.
Materials and Methods:
The methylation state of p16 gene promoter was measured by methylation specific PCR (MSP). A region containing CpG sites in p16 gene promoter was amplified by strand-specific polymerase chain reaction (PCR) after sodium bisulfite treatment.72 SLE cases and 20 healthy controls were enrolled. The state of DNA methylation in plasma and blood cells was detected and the corresponding clinical records were analyzed.
Results:
1、 p16 gene hypermethylation in SLE patients was showen by plasma DNA detection.
(1)There was a significant difference between SLE patients(29/45, 64.44%) and healthy individuals(1/20, 5%) (x~2=19.687~b; p=0, p<0.001; OR=34.44, 95%CI [19.25 ~ 49.63]) .It was found that the rate of DNA hypermethylation in active SLE patients was higher (20/24,83.33%) than that in inactive SLE patients (9/21,42.85%) (x~2= 8.008~b; P=0.005, <0.01; OR=6.67; 95%CI [2.05 ~ 11.29]). Only one healthy individual was detected DNA hyermethylation in plasma.
探讨系统性红斑狼疮(SLE)患者中p16基因启动子甲基化状态及其在发病机制中的作用。
方法
检测45例SLE患者血浆DNA甲基化状态、72例SLE患者全血细胞DNA甲基化状态，并以20名健康对照者血浆和全血细胞作为对照。应用甲基化特异PCR(MSP)方法检测p16基因启动子区甲基化状态，其原理为：DNA经亚硫酸氢钠修饰后，p16基因启动子区含CpG区域可以用PCR进行扩增。对扩增结果与患者疾病活动性、临床表现及常规实验室检查结果之间的关联进行分析。
结果
1、SLE患者血浆DNA中p16基因启动子呈现高甲基化状态：
(1)SLE组中p16基因启动子呈甲基化状态者占64.44％(29／45)，而健康对照组中只有1名检测到p16基因甲基化(1／20，5％)，两组间差异具有统计学意义(X~2=19.687~b，p＜0.001；OR=34.44；95％CI[19.25～49.63])。活动期SLE组p16基因呈甲基化状态者所占比率83.33％(20／24)比非活动期SLE组42.85％(9／21)高，差异也有明显统计学意义(x~2=8.008~b；P=0.005，＜0.01；OR=6.67)。
(2)初发SLE组p16基因启动子呈甲基化状态者所占比例(71.43％，15／21)，与复发SLE组(58.33％)相比差异没有统计学意义(p=0.371)。
Objectives:
To investigate the state of p16 gene DNA methylation in plasma from the patients with Systemic Lupus Erythematosus (SLE) and its clinical.
Materials and Methods:
The methylation state of p16 gene promoter was measured by methylation specific PCR (MSP). A region containing CpG sites in p16 gene promoter was amplified by strand-specific polymerase chain reaction (PCR) after sodium bisulfite treatment.72 SLE cases and 20 healthy controls were enrolled. The state of DNA methylation in plasma and blood cells was detected and the corresponding clinical records were analyzed.
Results:
1、 p16 gene hypermethylation in SLE patients was showen by plasma DNA detection.
(1)There was a significant difference between SLE patients(29/45, 64.44%) and healthy individuals(1/20, 5%) (x~2=19.687~b; p=0, p<0.001; OR=34.44, 95%CI [19.25 ~ 49.63]) .It was found that the rate of DNA hypermethylation in active SLE patients was higher (20/24,83.33%) than that in inactive SLE patients (9/21,42.85%) (x~2= 8.008~b; P=0.005, <0.01; OR=6.67; 95%CI [2.05 ~ 11.29]). Only one healthy individual was detected DNA hyermethylation in plasma.
引文
1、Herkel J, Mimran A, Erez N et al. Autoimmunity to the p53 Protein is a Feature of Systemic Lupus Erythematosus (SLE) Related to Anti-DNA Antibodies. J Autoimmunity, 2001, 17:63-69.
2、Kuo P, Bynoe MS, Wang C, Diamond B. Bc1-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. Eur J Immunol. 1999 29(10): 3168-78。
3、Mysler E, Bini P, Drappa J, et al. The apoptosis-1 Fas protein in human systemic lupus erythematosus. J Clin Invest. 1994; 93: 1029-34.
4、Singer GG. Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T-lymphocytes in T-cell receptor transgenic mice. Immunity, 1994; 1: 365-71.
5、Sherr C. J. Cancer cell cycles. Science, 1996, 274: 1672-1677.
6、Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/pl6/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995 15;55(20):4525-30.
7、Pilon C, Pistorello M, Moscon A et al. Inactivation of the p16 Tumor Suppressor Gene in Adrenocortical Tumors. The Journal of Clinical Endocrinology & Metabolism. 1999, 84:2776-2779.
8、Robertson KD. DNA methylation, methyltransterases, adcancer. Oncogene, 2001,20(24):3139-55.
9、Lyon MF. Imprinting and X-chromosome inactivation [J]. Results Probl Cell Differ, 1999,25:73-90.
10、Li E, et al. Nature, 1993,366:362-365.
11、Fang JY, Lu YY, et al. Effects of histoneacethlation and DNA methylation on P21 (WAF1) regulation. World J Gastroenterol, 2002,Jun:8(3): 400-5.
12、Jnes PA, laird PW, et al. Cancer epigenetics comes of age [J]. Na. Gene, 1999,21(2): 163-167.
13、Lewis JD, Meehan RR, Henzel WJ, et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell. 1992 Jun 12;69 (6):905-14.
14、Tamaru H, Selker EU, et al. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature. 2001 Nov 15; 414 (6861): 77-83. Jackson JP, Lindron AM, Cao X,??Jacobsen SE. Control of CpNpG DNA methylation by the KRYPTONTTE histone H3 methyltransferase. Nature. 2002 Apr 4; 416(6880): 556-60.
15、Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998 May 28; 393(6683): 386-9.
16、Esteller M. CpG island hypermethylation and tumor supperssor genes: a booming present, a brigher future. Oncogene, 2002, 21: 5427-5440.
17、Gonzalgo M L, Liang G, Spruck C H, et al. Identification and characterization of genomic DNA by methylation-sensitive arbitrarily primed PCR [J]. Cancer Res, 1997, 57: 594.
18、Bender C M, Zingg J M, et al. DNA methylaion as a target for durg design [J]. Pharmaceutical Res, 1998, 15: 175.
19、Yin D, Xie D, Hofmann WK, Zhang W, Asotra K, Wong R, Black KL, Koeffler HP. DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog, 2003 Jan; 36(1): 23-31.
20、Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D. Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis, 2003 Jun; 24(6): 1039-44.
21、Qian A, Liu Y, Gao Y et al. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Letters, 2002, 188: 109-114.
22、Richardson B, Scheinbart L, Strahlar J et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum, 1990, 33: 1665-1673.
23、Margarita SB, Abel SA, and Miguel AP. Cell cycle deregulation in B-cell lymphomas. Blood. 2003; 101: 1220-1235
24、Rountree MR, Selker EU. (). DNA methylation inhibits elongation but not initiation of transcription in Neurospora crassa. Genes. Dev. 1997, 11: 2383-2395.
25、Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 1993, 3: 226-231
26、Cross SH, Meehan RR, Nan X, et al. A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. Nat. Genet. 1997, 16: 256-259.??(modified from SINGAL et al. 1999).
27、Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982, 25: 1271-1277.
28、Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35: 630-640.
29、Herman JG, Graft JR, MyohAnen S, et al.Mathylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA, 1996, 93:9821-9826.
30、Shapiro B, Chakrabarty M, Cohn EM and Leon SA: Determination of circulating DNA levels in patients benign or malignant gastrointestinal disease. Cancer 51: 2116-2120, 1983.
31、Leon SA, Shapiro BD, Sklaroff M and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646-650, 1977.
32、Stroun P, Anker P, Lyautey J, Lederrey C and Maurice PA: Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 23:707-712, 1987
33、Chen XQ, Stroun M, Magnenat JL, et al: Microsatellite alternations in plasma DNA of small cell lung cancer patients. Nat Med 2: 1033-1035, 1996.
34、Nawroz H, Koch W, Anker P, Stroun M and Sidransky D: Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2: 1035-1037, 1996.
35、Steinman, C. R. Circulating DNA in systemic lupus erythematosus. Isolation and Characterization. J. Clin. Invest. 1984, 73:832-841.
36、Li, J. Z., and C. R. Steirtman. Plasma DNA in systemic lupus erythematosus. Arthritis Rheum. 1989, 32:726-733.
37、Hung, P. P., J. C. Mao, C. M. Ling, and L. R. Overby. Hybridization of Dane particle DNA with the free plasma DNA of hepatitis carriers. Nature (Lond.). 1975, 253:571-572.
38、Steinman CR. Circulating DNA in systemic lulputs erythematosuis. Association with central nervous system involvement and systemic vascullitides. Anm J Mlled. 1979, 67: 429-435.
39、Distelhorst CW, Cramer K, and Rogers JC. Selective release of excreted DNA sequences from phytohemagglutinin-stimulated human peripheral blood lyinphocytes: effects of trypsin and divalent cations. J Clin Invest. 1978, 61: 1204-1217.
40、Chartson AJ, and Reid BL. A review of cytoplasmic and cell surface DNA with consideration??of their origin. J Carbohydr Nucleosides. 1978, 5: 381-442.
41、Dennin RH. DNA of free and complexed origin in human plasma: concentration and length distribution. Klimi Wochen schr. 1979, 57: 451-456.
42、Tsumita T, and Iwabaga M. Fate of injected deoxvribonucleic acid in mice. Nature (Louid.). 1963, 198: 1088-1089.
43、Chused TM, Steinberg AD, and Talal N. The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immuntllol. 1973, 12: 465-476.
44、Hadjiyannaki K, and Lachmann PJ. The relation of deoxyribonuclease inhibitor levels to the occurrence of antinuclear antibodies in NZB/NZW mice. Clin Exp Inmnunol. 1972, 11: 291-295.
45、Liebling MR, and Barnett EV. Substrate competition between DNAase Ⅰ and anti-DNA antibody. Cliti Immuflnol Iiutinunopathol. 1977, 8: 80-89.
46、Peter MR and Charles RS. Endogenous Circulating DNA in Systemic Lupus Erythematosus. J Clin Invest. 1990, 86, 69-74
47、Sano H, Takai O, Harata N et al. Binding propertyes of human anti-DNA antibodies to cloned human DNA fragments. Stand J Immunol, 1989; 30:51-63.
48、Kitamura H, Shindo K, Sasabe M et al. Conformational change of DNA on the formation of DNA-anti-DNA antibody immune complex. Nucleic Acids Symp Ser, 1997, (37): 145-146.
49、Hans PS, Hans E and Manfred R. Interfron-?-Inducible Protein p16. Arthritis Rheumatism, 1994, (11):1672-1683.
50、Miret C, Font J, Molina R et al. Bcl-2 oncogene(B cell lymphoma/leukemia) levels correlate with systemic lupus erythematosus disease activeity. Anticancer Res, 1999, 19(4B):3073-6.
51、Richardson B, powers D, Hooper F, et al. Lymphocyte function-associated antigen loverexpression and T cell autoreactivity. Arthritis Rheum, 1994,37(9) : 1363-1372.
52、Sano H, Compton LJ, Shiomi N, et al. Low expression of human histocompatibility leukocyte antigen-DR is associated with hypermethylation of human histocompatibility leukocyte antigen-DR alpha gene regions in B cells from patients with systemic lupus erythematosus. J Clin Invest. 1985 Oct;76(4): 1314-22.
53、Niwa Y, Miyachi Y, Sakane T, Kanoh T, Taniguchi S. Methyltransferase and phospholipase A2 activity in the cell membrane of neutrophils and lymphocytes from patients with Behcet's disease, systemic lupus erythematosus, and rheumatoid arthritis. Clin Claim Acta. 1988 May 13; 174(1):??1-14.
54、Ivy H.N.Wang et al 1999
55、Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994; 7(4): 536-40.
56、Li Q et al 1998;
57、Jean-Pierre J et al 1996
58、Chen JT, Ho WL, Cheng YW, et al. Detection of p53 mutations in sputum smears precedes diagnosis of non-small cell lung carcinoma. Anticancer Res. 2000; 20(4): 2687-90
59、Silva JM, Dominguez G, Garcia JM, et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 1999 Jul 1; 59(13): 3251-6.
60、Somers VA, Pietersen AM, Theunissen PH, et al. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. J Clin Oncol. 1998; 16(9): 3061-8.
61、Miozzo M, Sozzi G. Musso K, et al. Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res. 1996, 15; 56(10): 2285-8.
62、Gonzalez R, Silva JM, Sanchez A, et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol. 2000; 11(9): 1097-104.
63、Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res. 1999 Oct; 5(10): 2689-92.
64、Kersting M, Friedl C, Kraus A, et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol. 2000 Sep 15; 18(18): 3221-9.
65、Widschwendter M, Jones PA. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin Cancer Res. 2002 Jan; 8(1): 17-21. 2002;
66、H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res., 8: 188-191, 2002.
67、Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001, 15; 61(12): 4675-??68、Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001 15 ;61 (4): 1659-65.
69、Wong IH, Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999 Jan 1 ;59(1):71-3.
70、Hibi K, Taguchi M, Nakayama H, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2001 Oct;7(10):3135-8.
71、An Q, Liu Y, Gao Y, et al. Deletion of tumor suppressor genes in Chinese non-small cell lung cancer. Cancer Lett. 2002 Oct 28; 184(2): 189-95.
72、Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999, 59(1):67-70
73、Michael W. Y et al 2002
74、Tsou JA, Hagen JA, Carpenter CL, et al. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002,21(35):5450-61.
75、Radoslaw J, Janusz P, Pawe P, et al. Role of epigenetic DNA alterations in the pathogenesis of systemic lupus erythematosus. J Appl Genet, 45(2), 2004, 237-248.
76、Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982, 25: 1271-1277.
77、Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35: 630-640.
78、徐冠东。肺癌标本中p16、MGM基因异常甲基化研究。(博士学位论文)．1、Viallard JF, Pellegrin JL, Ranchin V, et al. Thl (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) eytokine production by peripheral blood mononuelear ceils (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999 Jan; 115(1): 189-95.
2、Chart RW, Tam LS, Li EK, et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 2003 May; 48(5): 1326-31.
3、Uhm WS, Na K, Song GW, et al. Cytokine balance in kidney ti ssue from lupus nephritispatients. Rheumatology (Oxford). 2003 Aug; 42(8): 935-8. Epub 2003 Mar 31.
4、Chen S, Hu D, Shi X, et al. The relationship between Th1/Th2-type cells and disease activity in patients with systemic lupus erythematosus. Chin Med J (Engl). 2000 Oct; 113 (10): 877-80.
5、Min DJ, Cho ML, Cho CS,et al. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol. 2001 ;30(3): 159-63.
6、Baggiolini M. Chemokines and leukocyte traffic. Nature, 1998, 392 (6676) :565-568
7、Loetscher P, Seitz M, Baggiolini M, et al. Interleukin - 2 regulates CC chemokine receptor expression and chemotacticre sponsiveness in T lymphocytes. J Exp Med, 1996, 184 (2) :569-577.
8、Springer TA. Traffic signals for lymphocyte recireulation andleukocyte emigration: the multistep paradigm. Cell, 1994,76 (2):301-314.
9、Foxman EF, Campbell JJ, Butcher EC. Multistep navigationand the combinatorial control of leukocyte chemotaxis. J Cell Biol 1997, 139(5): 1349-1360.
10、Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T- cell priming and Th1/Th2 - mediated responses. Immunol Today, 1998,19(12) : 568-574.
11、Campbell JJ, Hedrick J, Zlotnik A, et al. Chemokines and the arrest of lymphocytes rollingunder flow conditions. Scinece, 1998, 279(5349): 381-384.
12、Luster SA, et al. Nat Immunol, 2001, 2: 102-107.
13、Sallusto F, et al. Annu Rev Immunol, 2000, 18: 593-620.
14、Loetscher P, Pellegrino A, Gong JH, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP-10, are natural antagonists for CCR3. J Bio Chem, 2001, 276(5): 2986-2991.15、Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today, 1998, 19(12): 568-574.
16、Luster AD. Curr Opin Immunol, 2002, 14: 129-135.
17、Cole KE, Strick CA, Paradis TJ, et al. Interferon - inducibleT cell alpha chemoattractant (I - TAC): a novel non - ELRCXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med, 1998, 187(12): 2009-2021.
18、Balashov KE, Rottman JB, Weiner HL, et al. CCR5(+)and CXCR3 (+) T cells are increased in multiple sclerosis and their ligands MIP - lalpha and IP - 10 are expressed indemyelinating brain lesions [J]. Proc Natl Acad Sci USA, 1999, 96(12): 6873-6889.
19、Sauty A, Dziejman M, Taha RA, et al. The T cell - specificCXC Chemokines IP - 10, Mig, and I - TAC are expressed by activated human bronchial epithelial cells. J Immunol, 1999, 162(6): 3549-3558.
20、Chensue SW, Warmington KS, Allenspach EJ, et al. Differen2 tial expression and cross - regulatory function of RANTES dur2ing mycobacterial (type 1) and schistosomal (type 2) antigen- elicited granulomatous inflammation. J Immunol, 1999, 163(1): 165-173.
21、Sallusto F, Mackay CR, Lanzavecchia A. Selective expres2sion of the eotaxin receptor CCR3 by human T helper 2 cells. Science, 1997, 277(5334): 2005-2007.
22、Jinquan T, Quan S, Feili G, et al. Eotaxin activates T cellsto chemotaxis and adhesion only if induced to express CCR3by IL - 2 together with IL - 4. J Immunol, 1999, 162(7): 4285-4292.
23、Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4 - bearing Th2 cells toward antigen - presenting cells by the CC chemokines thymus and activation - regulated chemokine and macrophage - derived chemokine. Int Immunol, 1999, 11(1): 81-88.
24、Bonecchi R, Bianchi G, Panina - Bordignon P, et al. Differential expression of chemokine receptors and chemotactic responsiveness in Th1 and Th2 cells. J Exp Med, 1998, 187(1): 129-134.
25、Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper land 2 lymphocytes. J Exp Med, 1998, 187(6): 875-883.
26、Zingoni A, Soto H, Hedrick JA, et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol, 1998, 161(2): 547-551.
27、Napolitano M, Santoni A. Structure and function of the CC chemokine receptor (CCR) 8.??Forum (Geneva). 1999 Oct-Dec; 9(4): 315-24.
28、Luster AD. Antichemokine immunotherapy for allergic diseases. Curr Opin Allergy Clin Immunol. 2001 Dec; 1(6): 561-7.
29、Varona R, Villares R, Carramolino L, et al. CCR6-deficient mice have impaired leukocyte homeostasiss and altered contact hypersensitivity and delayed-type hypersensitivity responses. J Clin Invest, 2001, 107(6): R37-45.
30、Amoura Z, Combadiere C, Faure S, et al. Role of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum, 2003, 48(12): 3487-96.
31、Perez de Lema G, Maier H, Nieto E, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001 Jul; 12(7): 1369-82.
32、Amoura Z, Combadiere C, Faure S, et al. Role of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum, 2003, 48(12): 3487-96.
33、Eriksson C, Eneslatt K, Ivanoff J, et al. Abnormal expression of chemokine on T-cells from patients with systemic lupus erythematosus. Lupus, 2003; 12(10): 766-74.
34、Nagase H, Miyamasu M, Yamaguchi M, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J Immunol. 2000, 164: 5935-5943.
35、Xie H, Lim YC, Luscinskas FW, et al. Acquisition of se2lectin binding and peripheral homing properties by CD4(+)and CD8(+) T cells. J Exp Med, 1999, 189(11): 1765-1776.
36、Bradley LM, Asensio VC, Schioetz LK, et al. Islet - specific Th1, but not Th2, cells secrete multiple chemokines andpromote rapid induction of autoimmune diabetes. J Immunol, 1999, 162(5): 2511-2520.
37、Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper land 2 lymphocytes. J Exp Med, 1998, 187(6): 875 -883.
38、Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper land 2 lymphocytes. J Exp Med, 1998, 187(6): 875 -883.
39、Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003 Oct; 14(5): 409-26.
40、Meissner A, Zilles O, Varona R, et al. CC chemokine ligand 20 partially controls adhesion of naive B cells to activated endothelial cells under shear stress. Blood. 2003 Oct 15; 102(8): 2724-7.??Epub 2003 Jun 19.
41、Ruth JH, Shahrara S, Park CC, et al.Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest. 2003 Apr;83(4):579-88.
42、Liao F, Shirakawa AK, Foley JF, et al.Human B cells become highly responsive to macrophage-inflammatory protein-3 alpha/CC chemokine ligand-20 after cellular activation without changes in CCR6 expression or ligand binding. J Immunol. 2002 May 15; 168(10):4871-80.
43、Napolitano M, Santoni A. Structure and function of the CC chemokine receptor (CCR) 8. Forum (Genova). 1999 Oct-Dec; 9(4):315-24.
44、Luster AD. Antichcmokine immunothcrapy for allergic diseases. Curt Opin Allergy Clin Immunol. 2001 Dec; 1(6): 561-7.
45、Foussat A, Coulomb HA, Gosling J, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol. 2000, 30: 87-97.
46、Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fi-actalkine-mediated cell adhesion and signal transduetion. J Biol Chem. 1999, 274: 10053-10058.
47、Fong AM, Robinson LA, Steeber DA, et al. Fraetalkine and CX3CR1 mediate a novel mechnism of leukocyte capture, firm adhesion, and activation underphysiolofic flow. J Exp Med. 1998, 188: 1413-1419.
48、Umehara H, Bloom ET, Okazald T, et al. Fraetalkine in vascular biology: from basic research to clinical disease. Arterioseler Thromb Vase Biol. 2004; 24(1):34-40. Epub 2003 Sep 11.
49、Wang CR, Liu MF, Huang YH, et al. Up-regulation of XCR1 expression in rheumatoid joints. Rheumatology (Oxford). 2004, 17 [Epub ahead of print]
50、Garin A, Tarantino N, Faure S, et al. Two novel fully functional isoforms of CX3CR1 are potent HIV eoreeeptors. J Immunol. 2003 Nov 15; 171(10):5305-12.
51、Chen YM, Hu-Tsal MI, Lin S, et al. Expression of CX3CL1/fractalkine by mesangial cells in vitro and in acute anti-ThyI glomerulonephritis in rats. Nephrol Dial Transplant. 2003 Dec;18(12):2505-14.
52、Blaschke S, Koziolek M, Schwarz A, et al. Proinflammatory role of fraetalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol. 2003 ; 30(9): 1918-27.
53、Narumi S, Takeuchi T, Kobayashi Y, et al. Serum levels of IFN-inducible protein-10 relating to??the activity of systemic lupus erythcmatosus. Cytokine, 2000, 12(10): 1561-1565.
54、Segerer S, Banas B, Womle M, et al. CXCR3 is involved in tubulointerstitial injury in human glomerulonephrtis. Am J Pathol. 2004, 164(2): 635-49.
55、Shiozawa F, Kasama T, Yajima N, et al. Enhanced expression of interferon-inducible protein10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL/1pr mice. Arthritis Res Ther, 2004, 6(1): R78-R86.
56、Amoura Z, Combadiere C, Faure S, et al. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum, 2003, 48(12): 3487-96.
57、Eriksson C, Eneslatt K, Ivanoff J, et al. Abnormal expression of chemokine on T-cells from patients with systemic lupus erythematosus. Lupus, 2003; 12(10): 766-74.
58、Ishikawa S, Sato T, Abe M, et al. Abrrant high expression of B lymphocyte chemokine(BLC/CXCL13) by C11b+CD11c dendritic cells in murine lupus and preferentiall chem.otaxis of B1 cells towards BLC. J Exp Med, 2001, 193(12): 1393-402.
59、Yoshida T, Imai T, Kakizaki M, et al. Identification of single C motif-1/lymphotacin receptor XCR1. J Biol Chem, 1998, 273(26): 16551-16554.
60、Kelner GS, Kennedy J, Bacon KB, et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science. 1994,266(5189): 1395-9.
61、Huang H, Li F, Cairns CM, et al. Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin. Bioehem Biophys Res Commun. 2001 Feb 23;281(2):378-82
62、Cerdan C, Devilard E, Xerri L, et al. The C-class chemokine lymphotactin eostimulates the apoptosis of human CD4(+)T cells. Blood. 2001 Apr 15;97(8):2205-12. analyses and eytokine-mediated regulation. J Immunol. 2000, 164: 5935-5943.
63、Ccrdan C, Serfling E, Olive D. The C-class chemokine, lymphotaetin, impairs the induction of Th1-type lymphokines in human CD4(+) T cells. Blood. 2000, 96(2):420-8.
64、Cerdan C, Devilard E, Xerri L, et al. The C-class chemokine lymphotactin costimulates the apoptosis of human CD4(+)T cells. Blood, 2001, 97(8): 2205-2212
65、Natori Y, Ou ZL, Yamamoto-Shuda Y, et al. Expression of lymphotactin mRNA in experimental crescentic glomerulonephritis. Clin Exp Immunol. 1998, 113(2):265-8.
66、Kurt RA, Bauck M, Harma S, et al. Role of C chemokine lymphotactin in mediating??recruitment of antigen-specific CD62L(lo) cells in vitro and in vivo. Cell Immunol. 2001;209(2):83-8.
67、Wang CR, Liu MF, Huang YH, et al. Up-regulation of XCR1 expression in rheumatoid joints. Rheumatology (Oxford). 2004,17 [Epub ahead of print]
68、Blaschke S, Middel P, Dorner BG, et al. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum. 2003 ;48(7): 1858-72.
69、Luster AD. Antichemokine immunotherapy for allergic diseases. Curt Opin Allergy Clin Immunol. 2001 Dec; 1(6):561-7.
70、Foxman EF, Campbell JJ, Butcher EC. Multistep navigationand the combinatorial control of leukocyte chemotaxis. JCell Biol, 1997,139(5) : 1349 - 1360.
71、Sallusto F, Lanzavecckia A, Mackay CR. Chemokines and chemokine receptors in T- cell priming and Thl/Th2 - medi2ated responses. Immunol Today, 1998,19(12) : 568 -574.
72、Balashov KE, Rottman JB, Weiner HI,, et al. CCR5(+)and CXCR3 (+) T cells are increased in multiple sclerosis and their ligands MIP - 1alpha and IP-10 are expressed indemyelinating brain lesions. Proc Natl Acad Sci USA, 1999,96(12) : 6873 - 6889.
73、Gdmaldi JC, Yu NX, Gmnig G, et al. Depletion of eosinophilsin mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J Leukoc Biol, 1999,65(6) :846-853.
74、Baggiolini M, Moser B. Blocking chemokine receptors. JExp Med, 1997,186(8) :1189-1191.
75、Chensue SW, Warmington KS, Allenspach EJ ,et al. Differen2 tial expression and crossregulatory function of RANTES dur2ing mycobacterial (type 1) and schistosomal (type 2) antigen- elicited granulomatous inflammation. J Immunol, 1999,163 (1) : 165-173.
76、Wada T, Furuichi K, Sakai N, et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. JAm Soc Nephrol, 2004 ; 15(4): 940-8.
77、Nagase H, Miyamasu M, Yamaguchi M, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J Immunol. 2000, 164: 5935-5943.
78、Huber TB, Reinhardt HC, Exner M, et al. Expression of functional CCR and CXCR chemoldne receptors in podocytes. J Immunol, 2002, 168:6244-6252
79、Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic??lupus erythematosus. Arthritis Rheum, 1982, 25: 1271-1277.
80、Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35:630-640.
81、Stohl W, et al. impaired recovery and cytolytie function of CD56+T and non-T ceils in systemic lupus erythematosus following in vitro polyelonal T cell stimulation: studied in unselected SLE patients and in monozygotic twins discordant for SLE. Arthritis Rheum, 1996, 39:356.
82、姚旭。系统性红斑狼疮患者TH2型细胞因子受体表达及其基因多态性的研究。(博士学位论文)41-49．
83、Sallusto F, Mackay CR, Lanzavecchia A. Science, 1997,277(5334) :2005-2007.
84、Bonecchi R, Bianchi G, Bordignon PP, et al. J Exp Med, 1998, 187(1) :129-134.
85、Sallusto F, Lenig D, Mackay CR, et al. J Exp Med, 1998, 187 (6): 875-883.
86、Jourdan P, Abbal C, Nora N, et al. J Immunol, 1998,160 (9) :4153-4157.
87、Colantonio L. Blood, 1999, 94 (9) :2981-2989,
88、Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T2cell priming and TH1 PTH2 - mediated responses. Immunol Today ,1998,19.(12) :568-574.
89、Bacon-KB, Oppeneim JJ. Chemokines in disease models and pathogenesis. Cytokine Growth Factor Rev, 1998, 9 (2) :167-173.
90、Loetscher P, Pellegrino A, Gong JH, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP-10, are natural antagonists for CCR3. J Bio Chem, 2001, 276(5) :2986-29911 Wolffe AP and Matzke MA. Epigenetics: Regulation through repression. Science, 1999, 286(15):481-486.
2 Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding rotein MeCP2 involves a histone deacetylase complex. Nature, 1998,393,(28) 386-389.
3 Guy J, Hendrieh B, Holmes, et al. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nature Genet,2001, 27, 322, 326
4 Gonzalgo ML, Hayashida T, Bender CM, et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res,1998,58: 1245-1252.
5 Chen D, Ma H, Hong H, et al. Regulation of transcription by a protein methyltransferase. Science, 1999, 284(25): 2174-2177.6 Snatoro R, Li Junwei and Gmmmt I. The nucleolar remodeling complex NoRC mediates heterochromadn formation and silencing of ribosomal gene transcription. Nature Genet, 2002, 32:393-396.
7 Lee JT, Davidow LS, Warshawsky D. Tsix, a gene antisense to Xist at the X-inactivation centre. Nature Genet, 1999, 21: 400-404.
8 Piyathilake CJ, Bell WC, Johanning GL, et al. The accumulation of ascorbic acid by squamous cell carcinomas of the lung and larynx is associated with global methylation of DNA. Cancer, 2000,89 (1):171-176.
9 Soares J, Pinto AE, Cunha CV, et al. Global DNA hypomethylation in breast carcinoma. Cancer, 1999:85: 112-118.
10 Gupta A, Godwin AK, Vanderveer L, et al. Hypomethylation of the synuclein ygene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 2003,63 : 64-673.
11 Goessl C, M filer M, and Miller K. Methylafion-specific PCR (MSP) for detection of turnout DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer and Prostatic Diseases ,2000, 3(suppl 1):S17.
12 Malone CS, Miner MD, Doerr JR, et al. C~mC(A/T)GG DNA methylation in mature B cell lymphoma gene silencing. PNAS, 2001,98(18):10404-10409.
13 Domann FE, Rice JC, Hendrix MJC, et al. Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer,2000,85: 805-810.
14 Lee MG, Kim HY, Byun DS, et al. Frequent epigenetic inactivativation of RASSFIA in human bladder carcinoma. Cancer Res , 2001, 61: 6688-6692.
15 Byun DS, Lee MG, Chae KS, et al. Frequent epigenetie inactivation of RASSFlA by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res, 2001,61: 7034-703&
16 Lo KW, Kwong J, Hui ABY, et al. High frequency of promotor hypermethylation of RASSFlA in nasopharyngeal carcinoma. Cancer Res,2001,61 (15) :3877-3881.
17 Kanaya T, Kyo S, Malda Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene,2003, 22: 2352-2360.
18 Cui H, Onyango P, Brandenburg S, et al. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res , 2002, 62, (15) 6442-6446.19 Richardson B, Scheinbart L, Strahler J, et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum, 1990, 33 (11):1665-1673.
20 Yung R, Chang S, Hemati N, et al. Mechanisms of Drug-Induced Lupus. Arthritis Rheum, 1997, 40(8):1436-1443.
21 Quddus J, Johnson KJ, Gavalchin J, et al. Treating activated CD_4~+ T cells with either of tow distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest, 1993,92:38-53.
22 Yoshida H, Yoshida M, Merino R, et al. 5-Azacytidine inhibits the lpr gene-induced lymphadenopathy and acceleration of lupus-like syndrome in MRL/MpJ-lpr/lpr mice. Eur. J. lmmunol.1990,20: 1989-1993.
23 Deng C, Kaplan MJ, Yang J, et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum, 2001, 44(2):397-407.
24 Richardson B, powers D, Hooper F, et al. Lymphocyte function-associated antigenl overexpression and T cell autoreactivity. Arthritis Rheum, 1994,37(9) :1363-1372.
25 Lu Q, Kaplan M, Ray D, et al. Demethylation of ITGAL(CDlla) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum, 2002, 46(5):1282.1291.
26 Gilkeson GS, Bloom DD, Pisetsky DS, et al. Molecular characterization of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. Jlmmun, 1993, 151 : 1353-1364.
27 Vallin H, Perers A, Aim GV, et al. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immun , 1999, 163: 6306-6313.1. Anthes JC, Richard C, West RE, et al. Functional Characterization of desloratadine and other??antihistamines in a Chinese Hamster Ovary(CHO) cell line that expresses the cloned human bronchial smooth muscle Cells(HBSMC). [abstract] J Allergy Clin Immunol, 2000, 104(lpt2):S385.
2. Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist.1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung, 2000,50:345-52.
3. Cardel (?) I, Ant on F, Beleta J, et al. Antlcholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle.Eur J Pharmacol, 1999,374:249-254.
4. Bayram H, Devalia JL,Khair DA, et al. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured bronchial epthelial cell. J Allergy Clin Immunol, 1999,104(1):93-9.
5. kleine-Tebbe J, Jostles C, Frank G,et al. Inhibition of IgE-and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxy-carbonyl-loratadine. J Allergy Clin Immunol, 1994,93:494-500.
6. Kreutner W, Hey JA,Chiu P, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist, 2nd communnication: lack of nervous system and cardiovascular effects. Arzneimittelforschung, 2000,50:441-8.
7. Banfield C, Padni D,Glue P, et al. Electrocardiographic effects of multiple high doses of desloratadine. J Allergy Clin Immunol,2000,104(1pt2):S383.
8. Hey J, Anthes J, Barnett A,et al. Preclinical cardiovascular and CNS salty profile of desloratadine,a selective and nonsedating histamine H1-receptor antagonist. J Allergy Clin Immunol, 2000,104(1pt2):S383.
9. Vuurrnan E, Ramaekers JG,Rikken G,et al.Desloratadine does not impair actual driving performance : a 3-way crossover comparison with diphenhydramin and placbo [abstract no. 945].Allergy,2000,55 Suppl,63:263-4.
10. Herron JM, Padhit D,Affrimet MB, et al. Dose-proportionality, linearity, and pharmackinetics of desloratadine in health y adults. J Allergy Clin immunol, 2000,104 (1pt2):S385.
11. Gupta S, Padhi D,Banfield C, et al. The effect of food on the oral bioavailability of??desloratadine. J Allergy Clin Immunol,2000,104(1pt2):S386-7.
12. Padhi D, Banfield C, Gupta S,et al. Multiple-dose pharmacokinetics,safty, and tolerance of desloratadine in healthy volunteers. J Allergy Clin Immunol, 2000,104 (1pt2):S385.
13. Raseuberg MA, Cohen A,Padhi D,et al. Multiple-dose pharmacokinetics, of desloratadine in subjects differing in race and gender. J Allergy Clin Imraunol,2000, 104 (1pt2):S386.
14. Affrime MB, Banfield C,Glue P, et al. Desloratadine and ketoconazole: pharmacokinetcs and electrocardiographic pharmacodynamic effects. J Allergy Clin Immunol, 2000, 104(lpt2):S386.
15. Glue P, Banfield C, Affrime MB,et al. Desloratadine and erythromycin: pharmacokinetcs and electrocardiographic pharmacodynamic effects. J Allergy Clin Immunol, 2000, 104(1pt2):S387.
16. Meltzer EO,Prenner BM,Nayak A,et al. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest, 2001,21(1):25-32.
17. Nayak A,Lorber R,Salmun LM. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis. J Allergy Immunol,2000,104(lpt2):S384.
18. Heithff K, Meltzer EO,Mellars L,et al. Desloratadine improves quality of life in patients with seasonal allergic rhinitis. J Allergy Clin Immunol,2000,104 (1pt2):S383-4.
19. Ring J,Hein R,Gauger A,et al.Desloratadine Study Group. One-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria:a randomized, double-blind, placebo-controlled study. Int J Dermatol, 2001,40:72-76.1. Davies JE,Dedhia HV, Morgade C.et al.Lindan poisonings.Arch Dermatol 1983;119:142-144
2. Ushav, DNB,and Gopalakrishnan T.V.A comparative study of oral ivermectin and topical permectin cream in the treatment of scabies.J Am Acad Dermatol 2000,42(2):236-40
3. Cully.D.F.,Vassilatis,D.K.,et al .Cloning of an avermectin-sensitive glutamate-gated chloride channel from caenorhabditis elegans.Nature, 1994,317:707-711
4. Arena,J.P.,Liu K.K.,Paress,P.S.,et al.The mechanism of action of avermectins in Caenorhabditis elegans:correlation between activation of glutamate-sensitive chloride current,memberane binding and biological activity.J.Parasitol., 1995,81:286-294.
5. Jaramillo-Ayerbe F and Berr (?)-Munoz.Ivermectin for crusted Norwegian scabies induced by use of topical steroids. Arch Dermatol 1998,134(Feb): 143-145
6. Schinkel A.H,Smit J.J.van Tellingen O,et al.Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitity to drugs .Cell, 1994,77:491-502
7. Meinking TL.Taplin D.Hermida JL,et al.The treatment of scabies with ivermectin.N Engl J Med 1995;333:26-30
8. Lepparad B and Naburi AE.The use of ivermectin in controlling an outbreat of scabies in a??prison.Br J Dermatol 2000; 143:520-523
9. Elmogy M,Fayed H,Marzok H,et al.Oral ivermectin in the treatment of scabies.Int J Dermatol. 1999;38:926-930
10. Aubin F and Humbert P.Ivermectin for crusted (Norwegian)scabies.N Engl J Med.1995;332:612
11. Gladstone HB and Darmstadt GL.Crusted scabies in an immunocompetend child:treatment with ivermectin.Pedia Dermatol 2000;17(2): 144-148
12. Cestadice P, Carles M,Couppie P, et al.Oral treatment of crusted scabies with ivermecffn:Report of two case.Pedia Dermatol 2000;17(5):410-414
13. Giudice P, Carles M,Couppie,et al.Successful treatment of crusted(Norwegian) scabies with ivermectin in two patients with human immunodeficiency virus infection.Br J Dermatol 1996;135:494
14. Dourmishev AL, Serafimova DK, et al.Crusted scabies of the scalp in dermatomyositis patients:three cases treated with oral ivermectin.Int J Dermatol 1998;37:231-234
15. Chouela EN,Abeldano AM,et al.Equivalent therapeutic efficacy and safety of ivermectin and lindan in the treatment of human scabies.Arch Dermatol 1999;135:651-655
16. Burkhart CG.Burkhart CN.Burkhart KM.An epidemiologic and therapeutic reassessment of scabies.Cuffs 2000,65(Apr):233-240
17. Gardon J,Gardon-Wendel N,et al.Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa Loa infection. Lancet 1997;350:18-22
18. Barkwell R,Shiels S.Deaths associated with ivermectin treatment of scabies. Lancet 1997;349:1144-1145
19. Giudice PD,Marty P, et al.Ivermetin in elderly patients. Arch Dermatol 1999 Mar;135(13):351-2
20. Hardman JL,Limbird LE.Drugs used in the chemotherapy of helminthiasis. The Pharmacological basis of therapeutics. 1996 9/e 1017-1018
21. Magda Y.M.,Youssee Hayam A.H.,et al.Topical application of ivermeetin for human ectoparasites.Am J Trop Hyg 1995 53(6):652-653
22. Forstinger C.,Kittler H.,and Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream.J Am Acad Dermatol 1999;41(5):775-777
2、Kuo P, Bynoe MS, Wang C, Diamond B. Bc1-2 leads to expression of anti-DNA B cells but no nephritis: a model for a clinical subset. Eur J Immunol. 1999 29(10): 3168-78。
3、Mysler E, Bini P, Drappa J, et al. The apoptosis-1 Fas protein in human systemic lupus erythematosus. J Clin Invest. 1994; 93: 1029-34.
4、Singer GG. Abbas AK. The Fas antigen is involved in peripheral but not thymic deletion of T-lymphocytes in T-cell receptor transgenic mice. Immunity, 1994; 1: 365-71.
5、Sherr C. J. Cancer cell cycles. Science, 1996, 274: 1672-1677.
6、Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/pl6/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995 15;55(20):4525-30.
7、Pilon C, Pistorello M, Moscon A et al. Inactivation of the p16 Tumor Suppressor Gene in Adrenocortical Tumors. The Journal of Clinical Endocrinology & Metabolism. 1999, 84:2776-2779.
8、Robertson KD. DNA methylation, methyltransterases, adcancer. Oncogene, 2001,20(24):3139-55.
9、Lyon MF. Imprinting and X-chromosome inactivation [J]. Results Probl Cell Differ, 1999,25:73-90.
10、Li E, et al. Nature, 1993,366:362-365.
11、Fang JY, Lu YY, et al. Effects of histoneacethlation and DNA methylation on P21 (WAF1) regulation. World J Gastroenterol, 2002,Jun:8(3): 400-5.
12、Jnes PA, laird PW, et al. Cancer epigenetics comes of age [J]. Na. Gene, 1999,21(2): 163-167.
13、Lewis JD, Meehan RR, Henzel WJ, et al. Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell. 1992 Jun 12;69 (6):905-14.
14、Tamaru H, Selker EU, et al. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature. 2001 Nov 15; 414 (6861): 77-83. Jackson JP, Lindron AM, Cao X,??Jacobsen SE. Control of CpNpG DNA methylation by the KRYPTONTTE histone H3 methyltransferase. Nature. 2002 Apr 4; 416(6880): 556-60.
15、Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998 May 28; 393(6683): 386-9.
16、Esteller M. CpG island hypermethylation and tumor supperssor genes: a booming present, a brigher future. Oncogene, 2002, 21: 5427-5440.
17、Gonzalgo M L, Liang G, Spruck C H, et al. Identification and characterization of genomic DNA by methylation-sensitive arbitrarily primed PCR [J]. Cancer Res, 1997, 57: 594.
18、Bender C M, Zingg J M, et al. DNA methylaion as a target for durg design [J]. Pharmaceutical Res, 1998, 15: 175.
19、Yin D, Xie D, Hofmann WK, Zhang W, Asotra K, Wong R, Black KL, Koeffler HP. DNA repair gene O6-methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog, 2003 Jan; 36(1): 23-31.
20、Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D. Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis, 2003 Jun; 24(6): 1039-44.
21、Qian A, Liu Y, Gao Y et al. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Letters, 2002, 188: 109-114.
22、Richardson B, Scheinbart L, Strahlar J et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum, 1990, 33: 1665-1673.
23、Margarita SB, Abel SA, and Miguel AP. Cell cycle deregulation in B-cell lymphomas. Blood. 2003; 101: 1220-1235
24、Rountree MR, Selker EU. (). DNA methylation inhibits elongation but not initiation of transcription in Neurospora crassa. Genes. Dev. 1997, 11: 2383-2395.
25、Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 1993, 3: 226-231
26、Cross SH, Meehan RR, Nan X, et al. A component of the transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and HRX proteins. Nat. Genet. 1997, 16: 256-259.??(modified from SINGAL et al. 1999).
27、Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982, 25: 1271-1277.
28、Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35: 630-640.
29、Herman JG, Graft JR, MyohAnen S, et al.Mathylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA, 1996, 93:9821-9826.
30、Shapiro B, Chakrabarty M, Cohn EM and Leon SA: Determination of circulating DNA levels in patients benign or malignant gastrointestinal disease. Cancer 51: 2116-2120, 1983.
31、Leon SA, Shapiro BD, Sklaroff M and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646-650, 1977.
32、Stroun P, Anker P, Lyautey J, Lederrey C and Maurice PA: Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 23:707-712, 1987
33、Chen XQ, Stroun M, Magnenat JL, et al: Microsatellite alternations in plasma DNA of small cell lung cancer patients. Nat Med 2: 1033-1035, 1996.
34、Nawroz H, Koch W, Anker P, Stroun M and Sidransky D: Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2: 1035-1037, 1996.
35、Steinman, C. R. Circulating DNA in systemic lupus erythematosus. Isolation and Characterization. J. Clin. Invest. 1984, 73:832-841.
36、Li, J. Z., and C. R. Steirtman. Plasma DNA in systemic lupus erythematosus. Arthritis Rheum. 1989, 32:726-733.
37、Hung, P. P., J. C. Mao, C. M. Ling, and L. R. Overby. Hybridization of Dane particle DNA with the free plasma DNA of hepatitis carriers. Nature (Lond.). 1975, 253:571-572.
38、Steinman CR. Circulating DNA in systemic lulputs erythematosuis. Association with central nervous system involvement and systemic vascullitides. Anm J Mlled. 1979, 67: 429-435.
39、Distelhorst CW, Cramer K, and Rogers JC. Selective release of excreted DNA sequences from phytohemagglutinin-stimulated human peripheral blood lyinphocytes: effects of trypsin and divalent cations. J Clin Invest. 1978, 61: 1204-1217.
40、Chartson AJ, and Reid BL. A review of cytoplasmic and cell surface DNA with consideration??of their origin. J Carbohydr Nucleosides. 1978, 5: 381-442.
41、Dennin RH. DNA of free and complexed origin in human plasma: concentration and length distribution. Klimi Wochen schr. 1979, 57: 451-456.
42、Tsumita T, and Iwabaga M. Fate of injected deoxvribonucleic acid in mice. Nature (Louid.). 1963, 198: 1088-1089.
43、Chused TM, Steinberg AD, and Talal N. The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immuntllol. 1973, 12: 465-476.
44、Hadjiyannaki K, and Lachmann PJ. The relation of deoxyribonuclease inhibitor levels to the occurrence of antinuclear antibodies in NZB/NZW mice. Clin Exp Inmnunol. 1972, 11: 291-295.
45、Liebling MR, and Barnett EV. Substrate competition between DNAase Ⅰ and anti-DNA antibody. Cliti Immuflnol Iiutinunopathol. 1977, 8: 80-89.
46、Peter MR and Charles RS. Endogenous Circulating DNA in Systemic Lupus Erythematosus. J Clin Invest. 1990, 86, 69-74
47、Sano H, Takai O, Harata N et al. Binding propertyes of human anti-DNA antibodies to cloned human DNA fragments. Stand J Immunol, 1989; 30:51-63.
48、Kitamura H, Shindo K, Sasabe M et al. Conformational change of DNA on the formation of DNA-anti-DNA antibody immune complex. Nucleic Acids Symp Ser, 1997, (37): 145-146.
49、Hans PS, Hans E and Manfred R. Interfron-?-Inducible Protein p16. Arthritis Rheumatism, 1994, (11):1672-1683.
50、Miret C, Font J, Molina R et al. Bcl-2 oncogene(B cell lymphoma/leukemia) levels correlate with systemic lupus erythematosus disease activeity. Anticancer Res, 1999, 19(4B):3073-6.
51、Richardson B, powers D, Hooper F, et al. Lymphocyte function-associated antigen loverexpression and T cell autoreactivity. Arthritis Rheum, 1994,37(9) : 1363-1372.
52、Sano H, Compton LJ, Shiomi N, et al. Low expression of human histocompatibility leukocyte antigen-DR is associated with hypermethylation of human histocompatibility leukocyte antigen-DR alpha gene regions in B cells from patients with systemic lupus erythematosus. J Clin Invest. 1985 Oct;76(4): 1314-22.
53、Niwa Y, Miyachi Y, Sakane T, Kanoh T, Taniguchi S. Methyltransferase and phospholipase A2 activity in the cell membrane of neutrophils and lymphocytes from patients with Behcet's disease, systemic lupus erythematosus, and rheumatoid arthritis. Clin Claim Acta. 1988 May 13; 174(1):??1-14.
54、Ivy H.N.Wang et al 1999
55、Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994; 7(4): 536-40.
56、Li Q et al 1998;
57、Jean-Pierre J et al 1996
58、Chen JT, Ho WL, Cheng YW, et al. Detection of p53 mutations in sputum smears precedes diagnosis of non-small cell lung carcinoma. Anticancer Res. 2000; 20(4): 2687-90
59、Silva JM, Dominguez G, Garcia JM, et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 1999 Jul 1; 59(13): 3251-6.
60、Somers VA, Pietersen AM, Theunissen PH, et al. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. J Clin Oncol. 1998; 16(9): 3061-8.
61、Miozzo M, Sozzi G. Musso K, et al. Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res. 1996, 15; 56(10): 2285-8.
62、Gonzalez R, Silva JM, Sanchez A, et al. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance. Ann Oncol. 2000; 11(9): 1097-104.
63、Sozzi G, Musso K, Ratcliffe C, et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res. 1999 Oct; 5(10): 2689-92.
64、Kersting M, Friedl C, Kraus A, et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol. 2000 Sep 15; 18(18): 3221-9.
65、Widschwendter M, Jones PA. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin Cancer Res. 2002 Jan; 8(1): 17-21. 2002;
66、H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res., 8: 188-191, 2002.
67、Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001, 15; 61(12): 4675-??68、Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001 15 ;61 (4): 1659-65.
69、Wong IH, Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 1999 Jan 1 ;59(1):71-3.
70、Hibi K, Taguchi M, Nakayama H, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2001 Oct;7(10):3135-8.
71、An Q, Liu Y, Gao Y, et al. Deletion of tumor suppressor genes in Chinese non-small cell lung cancer. Cancer Lett. 2002 Oct 28; 184(2): 189-95.
72、Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999, 59(1):67-70
73、Michael W. Y et al 2002
74、Tsou JA, Hagen JA, Carpenter CL, et al. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002,21(35):5450-61.
75、Radoslaw J, Janusz P, Pawe P, et al. Role of epigenetic DNA alterations in the pathogenesis of systemic lupus erythematosus. J Appl Genet, 45(2), 2004, 237-248.
76、Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982, 25: 1271-1277.
77、Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35: 630-640.
78、徐冠东。肺癌标本中p16、MGM基因异常甲基化研究。(博士学位论文)．1、Viallard JF, Pellegrin JL, Ranchin V, et al. Thl (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) eytokine production by peripheral blood mononuelear ceils (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999 Jan; 115(1): 189-95.
2、Chart RW, Tam LS, Li EK, et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum. 2003 May; 48(5): 1326-31.
3、Uhm WS, Na K, Song GW, et al. Cytokine balance in kidney ti ssue from lupus nephritispatients. Rheumatology (Oxford). 2003 Aug; 42(8): 935-8. Epub 2003 Mar 31.
4、Chen S, Hu D, Shi X, et al. The relationship between Th1/Th2-type cells and disease activity in patients with systemic lupus erythematosus. Chin Med J (Engl). 2000 Oct; 113 (10): 877-80.
5、Min DJ, Cho ML, Cho CS,et al. Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol. 2001 ;30(3): 159-63.
6、Baggiolini M. Chemokines and leukocyte traffic. Nature, 1998, 392 (6676) :565-568
7、Loetscher P, Seitz M, Baggiolini M, et al. Interleukin - 2 regulates CC chemokine receptor expression and chemotacticre sponsiveness in T lymphocytes. J Exp Med, 1996, 184 (2) :569-577.
8、Springer TA. Traffic signals for lymphocyte recireulation andleukocyte emigration: the multistep paradigm. Cell, 1994,76 (2):301-314.
9、Foxman EF, Campbell JJ, Butcher EC. Multistep navigationand the combinatorial control of leukocyte chemotaxis. J Cell Biol 1997, 139(5): 1349-1360.
10、Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T- cell priming and Th1/Th2 - mediated responses. Immunol Today, 1998,19(12) : 568-574.
11、Campbell JJ, Hedrick J, Zlotnik A, et al. Chemokines and the arrest of lymphocytes rollingunder flow conditions. Scinece, 1998, 279(5349): 381-384.
12、Luster SA, et al. Nat Immunol, 2001, 2: 102-107.
13、Sallusto F, et al. Annu Rev Immunol, 2000, 18: 593-620.
14、Loetscher P, Pellegrino A, Gong JH, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP-10, are natural antagonists for CCR3. J Bio Chem, 2001, 276(5): 2986-2991.15、Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today, 1998, 19(12): 568-574.
16、Luster AD. Curr Opin Immunol, 2002, 14: 129-135.
17、Cole KE, Strick CA, Paradis TJ, et al. Interferon - inducibleT cell alpha chemoattractant (I - TAC): a novel non - ELRCXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med, 1998, 187(12): 2009-2021.
18、Balashov KE, Rottman JB, Weiner HL, et al. CCR5(+)and CXCR3 (+) T cells are increased in multiple sclerosis and their ligands MIP - lalpha and IP - 10 are expressed indemyelinating brain lesions [J]. Proc Natl Acad Sci USA, 1999, 96(12): 6873-6889.
19、Sauty A, Dziejman M, Taha RA, et al. The T cell - specificCXC Chemokines IP - 10, Mig, and I - TAC are expressed by activated human bronchial epithelial cells. J Immunol, 1999, 162(6): 3549-3558.
20、Chensue SW, Warmington KS, Allenspach EJ, et al. Differen2 tial expression and cross - regulatory function of RANTES dur2ing mycobacterial (type 1) and schistosomal (type 2) antigen- elicited granulomatous inflammation. J Immunol, 1999, 163(1): 165-173.
21、Sallusto F, Mackay CR, Lanzavecchia A. Selective expres2sion of the eotaxin receptor CCR3 by human T helper 2 cells. Science, 1997, 277(5334): 2005-2007.
22、Jinquan T, Quan S, Feili G, et al. Eotaxin activates T cellsto chemotaxis and adhesion only if induced to express CCR3by IL - 2 together with IL - 4. J Immunol, 1999, 162(7): 4285-4292.
23、Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4 - bearing Th2 cells toward antigen - presenting cells by the CC chemokines thymus and activation - regulated chemokine and macrophage - derived chemokine. Int Immunol, 1999, 11(1): 81-88.
24、Bonecchi R, Bianchi G, Panina - Bordignon P, et al. Differential expression of chemokine receptors and chemotactic responsiveness in Th1 and Th2 cells. J Exp Med, 1998, 187(1): 129-134.
25、Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper land 2 lymphocytes. J Exp Med, 1998, 187(6): 875-883.
26、Zingoni A, Soto H, Hedrick JA, et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol, 1998, 161(2): 547-551.
27、Napolitano M, Santoni A. Structure and function of the CC chemokine receptor (CCR) 8.??Forum (Geneva). 1999 Oct-Dec; 9(4): 315-24.
28、Luster AD. Antichemokine immunotherapy for allergic diseases. Curr Opin Allergy Clin Immunol. 2001 Dec; 1(6): 561-7.
29、Varona R, Villares R, Carramolino L, et al. CCR6-deficient mice have impaired leukocyte homeostasiss and altered contact hypersensitivity and delayed-type hypersensitivity responses. J Clin Invest, 2001, 107(6): R37-45.
30、Amoura Z, Combadiere C, Faure S, et al. Role of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum, 2003, 48(12): 3487-96.
31、Perez de Lema G, Maier H, Nieto E, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001 Jul; 12(7): 1369-82.
32、Amoura Z, Combadiere C, Faure S, et al. Role of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum, 2003, 48(12): 3487-96.
33、Eriksson C, Eneslatt K, Ivanoff J, et al. Abnormal expression of chemokine on T-cells from patients with systemic lupus erythematosus. Lupus, 2003; 12(10): 766-74.
34、Nagase H, Miyamasu M, Yamaguchi M, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J Immunol. 2000, 164: 5935-5943.
35、Xie H, Lim YC, Luscinskas FW, et al. Acquisition of se2lectin binding and peripheral homing properties by CD4(+)and CD8(+) T cells. J Exp Med, 1999, 189(11): 1765-1776.
36、Bradley LM, Asensio VC, Schioetz LK, et al. Islet - specific Th1, but not Th2, cells secrete multiple chemokines andpromote rapid induction of autoimmune diabetes. J Immunol, 1999, 162(5): 2511-2520.
37、Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper land 2 lymphocytes. J Exp Med, 1998, 187(6): 875 -883.
38、Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper land 2 lymphocytes. J Exp Med, 1998, 187(6): 875 -883.
39、Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003 Oct; 14(5): 409-26.
40、Meissner A, Zilles O, Varona R, et al. CC chemokine ligand 20 partially controls adhesion of naive B cells to activated endothelial cells under shear stress. Blood. 2003 Oct 15; 102(8): 2724-7.??Epub 2003 Jun 19.
41、Ruth JH, Shahrara S, Park CC, et al.Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest. 2003 Apr;83(4):579-88.
42、Liao F, Shirakawa AK, Foley JF, et al.Human B cells become highly responsive to macrophage-inflammatory protein-3 alpha/CC chemokine ligand-20 after cellular activation without changes in CCR6 expression or ligand binding. J Immunol. 2002 May 15; 168(10):4871-80.
43、Napolitano M, Santoni A. Structure and function of the CC chemokine receptor (CCR) 8. Forum (Genova). 1999 Oct-Dec; 9(4):315-24.
44、Luster AD. Antichcmokine immunothcrapy for allergic diseases. Curt Opin Allergy Clin Immunol. 2001 Dec; 1(6): 561-7.
45、Foussat A, Coulomb HA, Gosling J, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol. 2000, 30: 87-97.
46、Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fi-actalkine-mediated cell adhesion and signal transduetion. J Biol Chem. 1999, 274: 10053-10058.
47、Fong AM, Robinson LA, Steeber DA, et al. Fraetalkine and CX3CR1 mediate a novel mechnism of leukocyte capture, firm adhesion, and activation underphysiolofic flow. J Exp Med. 1998, 188: 1413-1419.
48、Umehara H, Bloom ET, Okazald T, et al. Fraetalkine in vascular biology: from basic research to clinical disease. Arterioseler Thromb Vase Biol. 2004; 24(1):34-40. Epub 2003 Sep 11.
49、Wang CR, Liu MF, Huang YH, et al. Up-regulation of XCR1 expression in rheumatoid joints. Rheumatology (Oxford). 2004, 17 [Epub ahead of print]
50、Garin A, Tarantino N, Faure S, et al. Two novel fully functional isoforms of CX3CR1 are potent HIV eoreeeptors. J Immunol. 2003 Nov 15; 171(10):5305-12.
51、Chen YM, Hu-Tsal MI, Lin S, et al. Expression of CX3CL1/fractalkine by mesangial cells in vitro and in acute anti-ThyI glomerulonephritis in rats. Nephrol Dial Transplant. 2003 Dec;18(12):2505-14.
52、Blaschke S, Koziolek M, Schwarz A, et al. Proinflammatory role of fraetalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol. 2003 ; 30(9): 1918-27.
53、Narumi S, Takeuchi T, Kobayashi Y, et al. Serum levels of IFN-inducible protein-10 relating to??the activity of systemic lupus erythcmatosus. Cytokine, 2000, 12(10): 1561-1565.
54、Segerer S, Banas B, Womle M, et al. CXCR3 is involved in tubulointerstitial injury in human glomerulonephrtis. Am J Pathol. 2004, 164(2): 635-49.
55、Shiozawa F, Kasama T, Yajima N, et al. Enhanced expression of interferon-inducible protein10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL/1pr mice. Arthritis Res Ther, 2004, 6(1): R78-R86.
56、Amoura Z, Combadiere C, Faure S, et al. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum, 2003, 48(12): 3487-96.
57、Eriksson C, Eneslatt K, Ivanoff J, et al. Abnormal expression of chemokine on T-cells from patients with systemic lupus erythematosus. Lupus, 2003; 12(10): 766-74.
58、Ishikawa S, Sato T, Abe M, et al. Abrrant high expression of B lymphocyte chemokine(BLC/CXCL13) by C11b+CD11c dendritic cells in murine lupus and preferentiall chem.otaxis of B1 cells towards BLC. J Exp Med, 2001, 193(12): 1393-402.
59、Yoshida T, Imai T, Kakizaki M, et al. Identification of single C motif-1/lymphotacin receptor XCR1. J Biol Chem, 1998, 273(26): 16551-16554.
60、Kelner GS, Kennedy J, Bacon KB, et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science. 1994,266(5189): 1395-9.
61、Huang H, Li F, Cairns CM, et al. Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin. Bioehem Biophys Res Commun. 2001 Feb 23;281(2):378-82
62、Cerdan C, Devilard E, Xerri L, et al. The C-class chemokine lymphotactin eostimulates the apoptosis of human CD4(+)T cells. Blood. 2001 Apr 15;97(8):2205-12. analyses and eytokine-mediated regulation. J Immunol. 2000, 164: 5935-5943.
63、Ccrdan C, Serfling E, Olive D. The C-class chemokine, lymphotaetin, impairs the induction of Th1-type lymphokines in human CD4(+) T cells. Blood. 2000, 96(2):420-8.
64、Cerdan C, Devilard E, Xerri L, et al. The C-class chemokine lymphotactin costimulates the apoptosis of human CD4(+)T cells. Blood, 2001, 97(8): 2205-2212
65、Natori Y, Ou ZL, Yamamoto-Shuda Y, et al. Expression of lymphotactin mRNA in experimental crescentic glomerulonephritis. Clin Exp Immunol. 1998, 113(2):265-8.
66、Kurt RA, Bauck M, Harma S, et al. Role of C chemokine lymphotactin in mediating??recruitment of antigen-specific CD62L(lo) cells in vitro and in vivo. Cell Immunol. 2001;209(2):83-8.
67、Wang CR, Liu MF, Huang YH, et al. Up-regulation of XCR1 expression in rheumatoid joints. Rheumatology (Oxford). 2004,17 [Epub ahead of print]
68、Blaschke S, Middel P, Dorner BG, et al. Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum. 2003 ;48(7): 1858-72.
69、Luster AD. Antichemokine immunotherapy for allergic diseases. Curt Opin Allergy Clin Immunol. 2001 Dec; 1(6):561-7.
70、Foxman EF, Campbell JJ, Butcher EC. Multistep navigationand the combinatorial control of leukocyte chemotaxis. JCell Biol, 1997,139(5) : 1349 - 1360.
71、Sallusto F, Lanzavecckia A, Mackay CR. Chemokines and chemokine receptors in T- cell priming and Thl/Th2 - medi2ated responses. Immunol Today, 1998,19(12) : 568 -574.
72、Balashov KE, Rottman JB, Weiner HI,, et al. CCR5(+)and CXCR3 (+) T cells are increased in multiple sclerosis and their ligands MIP - 1alpha and IP-10 are expressed indemyelinating brain lesions. Proc Natl Acad Sci USA, 1999,96(12) : 6873 - 6889.
73、Gdmaldi JC, Yu NX, Gmnig G, et al. Depletion of eosinophilsin mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J Leukoc Biol, 1999,65(6) :846-853.
74、Baggiolini M, Moser B. Blocking chemokine receptors. JExp Med, 1997,186(8) :1189-1191.
75、Chensue SW, Warmington KS, Allenspach EJ ,et al. Differen2 tial expression and crossregulatory function of RANTES dur2ing mycobacterial (type 1) and schistosomal (type 2) antigen- elicited granulomatous inflammation. J Immunol, 1999,163 (1) : 165-173.
76、Wada T, Furuichi K, Sakai N, et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. JAm Soc Nephrol, 2004 ; 15(4): 940-8.
77、Nagase H, Miyamasu M, Yamaguchi M, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J Immunol. 2000, 164: 5935-5943.
78、Huber TB, Reinhardt HC, Exner M, et al. Expression of functional CCR and CXCR chemoldne receptors in podocytes. J Immunol, 2002, 168:6244-6252
79、Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic??lupus erythematosus. Arthritis Rheum, 1982, 25: 1271-1277.
80、Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35:630-640.
81、Stohl W, et al. impaired recovery and cytolytie function of CD56+T and non-T ceils in systemic lupus erythematosus following in vitro polyelonal T cell stimulation: studied in unselected SLE patients and in monozygotic twins discordant for SLE. Arthritis Rheum, 1996, 39:356.
82、姚旭。系统性红斑狼疮患者TH2型细胞因子受体表达及其基因多态性的研究。(博士学位论文)41-49．
83、Sallusto F, Mackay CR, Lanzavecchia A. Science, 1997,277(5334) :2005-2007.
84、Bonecchi R, Bianchi G, Bordignon PP, et al. J Exp Med, 1998, 187(1) :129-134.
85、Sallusto F, Lenig D, Mackay CR, et al. J Exp Med, 1998, 187 (6): 875-883.
86、Jourdan P, Abbal C, Nora N, et al. J Immunol, 1998,160 (9) :4153-4157.
87、Colantonio L. Blood, 1999, 94 (9) :2981-2989,
88、Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T2cell priming and TH1 PTH2 - mediated responses. Immunol Today ,1998,19.(12) :568-574.
89、Bacon-KB, Oppeneim JJ. Chemokines in disease models and pathogenesis. Cytokine Growth Factor Rev, 1998, 9 (2) :167-173.
90、Loetscher P, Pellegrino A, Gong JH, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP-10, are natural antagonists for CCR3. J Bio Chem, 2001, 276(5) :2986-29911 Wolffe AP and Matzke MA. Epigenetics: Regulation through repression. Science, 1999, 286(15):481-486.
2 Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding rotein MeCP2 involves a histone deacetylase complex. Nature, 1998,393,(28) 386-389.
3 Guy J, Hendrieh B, Holmes, et al. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nature Genet,2001, 27, 322, 326
4 Gonzalgo ML, Hayashida T, Bender CM, et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res,1998,58: 1245-1252.
5 Chen D, Ma H, Hong H, et al. Regulation of transcription by a protein methyltransferase. Science, 1999, 284(25): 2174-2177.6 Snatoro R, Li Junwei and Gmmmt I. The nucleolar remodeling complex NoRC mediates heterochromadn formation and silencing of ribosomal gene transcription. Nature Genet, 2002, 32:393-396.
7 Lee JT, Davidow LS, Warshawsky D. Tsix, a gene antisense to Xist at the X-inactivation centre. Nature Genet, 1999, 21: 400-404.
8 Piyathilake CJ, Bell WC, Johanning GL, et al. The accumulation of ascorbic acid by squamous cell carcinomas of the lung and larynx is associated with global methylation of DNA. Cancer, 2000,89 (1):171-176.
9 Soares J, Pinto AE, Cunha CV, et al. Global DNA hypomethylation in breast carcinoma. Cancer, 1999:85: 112-118.
10 Gupta A, Godwin AK, Vanderveer L, et al. Hypomethylation of the synuclein ygene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 2003,63 : 64-673.
11 Goessl C, M filer M, and Miller K. Methylafion-specific PCR (MSP) for detection of turnout DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer and Prostatic Diseases ,2000, 3(suppl 1):S17.
12 Malone CS, Miner MD, Doerr JR, et al. C~mC(A/T)GG DNA methylation in mature B cell lymphoma gene silencing. PNAS, 2001,98(18):10404-10409.
13 Domann FE, Rice JC, Hendrix MJC, et al. Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer,2000,85: 805-810.
14 Lee MG, Kim HY, Byun DS, et al. Frequent epigenetic inactivativation of RASSFIA in human bladder carcinoma. Cancer Res , 2001, 61: 6688-6692.
15 Byun DS, Lee MG, Chae KS, et al. Frequent epigenetie inactivation of RASSFlA by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res, 2001,61: 7034-703&
16 Lo KW, Kwong J, Hui ABY, et al. High frequency of promotor hypermethylation of RASSFlA in nasopharyngeal carcinoma. Cancer Res,2001,61 (15) :3877-3881.
17 Kanaya T, Kyo S, Malda Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene,2003, 22: 2352-2360.
18 Cui H, Onyango P, Brandenburg S, et al. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res , 2002, 62, (15) 6442-6446.19 Richardson B, Scheinbart L, Strahler J, et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum, 1990, 33 (11):1665-1673.
20 Yung R, Chang S, Hemati N, et al. Mechanisms of Drug-Induced Lupus. Arthritis Rheum, 1997, 40(8):1436-1443.
21 Quddus J, Johnson KJ, Gavalchin J, et al. Treating activated CD_4~+ T cells with either of tow distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest, 1993,92:38-53.
22 Yoshida H, Yoshida M, Merino R, et al. 5-Azacytidine inhibits the lpr gene-induced lymphadenopathy and acceleration of lupus-like syndrome in MRL/MpJ-lpr/lpr mice. Eur. J. lmmunol.1990,20: 1989-1993.
23 Deng C, Kaplan MJ, Yang J, et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum, 2001, 44(2):397-407.
24 Richardson B, powers D, Hooper F, et al. Lymphocyte function-associated antigenl overexpression and T cell autoreactivity. Arthritis Rheum, 1994,37(9) :1363-1372.
25 Lu Q, Kaplan M, Ray D, et al. Demethylation of ITGAL(CDlla) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum, 2002, 46(5):1282.1291.
26 Gilkeson GS, Bloom DD, Pisetsky DS, et al. Molecular characterization of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. Jlmmun, 1993, 151 : 1353-1364.
27 Vallin H, Perers A, Aim GV, et al. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-α inducer in systemic lupus erythematosus. J Immun , 1999, 163: 6306-6313.1. Anthes JC, Richard C, West RE, et al. Functional Characterization of desloratadine and other??antihistamines in a Chinese Hamster Ovary(CHO) cell line that expresses the cloned human bronchial smooth muscle Cells(HBSMC). [abstract] J Allergy Clin Immunol, 2000, 104(lpt2):S385.
2. Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist.1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung, 2000,50:345-52.
3. Cardel (?) I, Ant on F, Beleta J, et al. Antlcholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle.Eur J Pharmacol, 1999,374:249-254.
4. Bayram H, Devalia JL,Khair DA, et al. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured bronchial epthelial cell. J Allergy Clin Immunol, 1999,104(1):93-9.
5. kleine-Tebbe J, Jostles C, Frank G,et al. Inhibition of IgE-and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxy-carbonyl-loratadine. J Allergy Clin Immunol, 1994,93:494-500.
6. Kreutner W, Hey JA,Chiu P, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist, 2nd communnication: lack of nervous system and cardiovascular effects. Arzneimittelforschung, 2000,50:441-8.
7. Banfield C, Padni D,Glue P, et al. Electrocardiographic effects of multiple high doses of desloratadine. J Allergy Clin Immunol,2000,104(1pt2):S383.
8. Hey J, Anthes J, Barnett A,et al. Preclinical cardiovascular and CNS salty profile of desloratadine,a selective and nonsedating histamine H1-receptor antagonist. J Allergy Clin Immunol, 2000,104(1pt2):S383.
9. Vuurrnan E, Ramaekers JG,Rikken G,et al.Desloratadine does not impair actual driving performance : a 3-way crossover comparison with diphenhydramin and placbo [abstract no. 945].Allergy,2000,55 Suppl,63:263-4.
10. Herron JM, Padhit D,Affrimet MB, et al. Dose-proportionality, linearity, and pharmackinetics of desloratadine in health y adults. J Allergy Clin immunol, 2000,104 (1pt2):S385.
11. Gupta S, Padhi D,Banfield C, et al. The effect of food on the oral bioavailability of??desloratadine. J Allergy Clin Immunol,2000,104(1pt2):S386-7.
12. Padhi D, Banfield C, Gupta S,et al. Multiple-dose pharmacokinetics,safty, and tolerance of desloratadine in healthy volunteers. J Allergy Clin Immunol, 2000,104 (1pt2):S385.
13. Raseuberg MA, Cohen A,Padhi D,et al. Multiple-dose pharmacokinetics, of desloratadine in subjects differing in race and gender. J Allergy Clin Imraunol,2000, 104 (1pt2):S386.
14. Affrime MB, Banfield C,Glue P, et al. Desloratadine and ketoconazole: pharmacokinetcs and electrocardiographic pharmacodynamic effects. J Allergy Clin Immunol, 2000, 104(lpt2):S386.
15. Glue P, Banfield C, Affrime MB,et al. Desloratadine and erythromycin: pharmacokinetcs and electrocardiographic pharmacodynamic effects. J Allergy Clin Immunol, 2000, 104(1pt2):S387.
16. Meltzer EO,Prenner BM,Nayak A,et al. Efficacy and tolerability of once-daily 5mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest, 2001,21(1):25-32.
17. Nayak A,Lorber R,Salmun LM. Decongestant effects of desloratadine in patients with seasonal allergic rhinitis. J Allergy Immunol,2000,104(lpt2):S384.
18. Heithff K, Meltzer EO,Mellars L,et al. Desloratadine improves quality of life in patients with seasonal allergic rhinitis. J Allergy Clin Immunol,2000,104 (1pt2):S383-4.
19. Ring J,Hein R,Gauger A,et al.Desloratadine Study Group. One-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria:a randomized, double-blind, placebo-controlled study. Int J Dermatol, 2001,40:72-76.1. Davies JE,Dedhia HV, Morgade C.et al.Lindan poisonings.Arch Dermatol 1983;119:142-144
2. Ushav, DNB,and Gopalakrishnan T.V.A comparative study of oral ivermectin and topical permectin cream in the treatment of scabies.J Am Acad Dermatol 2000,42(2):236-40
3. Cully.D.F.,Vassilatis,D.K.,et al .Cloning of an avermectin-sensitive glutamate-gated chloride channel from caenorhabditis elegans.Nature, 1994,317:707-711
4. Arena,J.P.,Liu K.K.,Paress,P.S.,et al.The mechanism of action of avermectins in Caenorhabditis elegans:correlation between activation of glutamate-sensitive chloride current,memberane binding and biological activity.J.Parasitol., 1995,81:286-294.
5. Jaramillo-Ayerbe F and Berr (?)-Munoz.Ivermectin for crusted Norwegian scabies induced by use of topical steroids. Arch Dermatol 1998,134(Feb): 143-145
6. Schinkel A.H,Smit J.J.van Tellingen O,et al.Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitity to drugs .Cell, 1994,77:491-502
7. Meinking TL.Taplin D.Hermida JL,et al.The treatment of scabies with ivermectin.N Engl J Med 1995;333:26-30
8. Lepparad B and Naburi AE.The use of ivermectin in controlling an outbreat of scabies in a??prison.Br J Dermatol 2000; 143:520-523
9. Elmogy M,Fayed H,Marzok H,et al.Oral ivermectin in the treatment of scabies.Int J Dermatol. 1999;38:926-930
10. Aubin F and Humbert P.Ivermectin for crusted (Norwegian)scabies.N Engl J Med.1995;332:612
11. Gladstone HB and Darmstadt GL.Crusted scabies in an immunocompetend child:treatment with ivermectin.Pedia Dermatol 2000;17(2): 144-148
12. Cestadice P, Carles M,Couppie P, et al.Oral treatment of crusted scabies with ivermecffn:Report of two case.Pedia Dermatol 2000;17(5):410-414
13. Giudice P, Carles M,Couppie,et al.Successful treatment of crusted(Norwegian) scabies with ivermectin in two patients with human immunodeficiency virus infection.Br J Dermatol 1996;135:494
14. Dourmishev AL, Serafimova DK, et al.Crusted scabies of the scalp in dermatomyositis patients:three cases treated with oral ivermectin.Int J Dermatol 1998;37:231-234
15. Chouela EN,Abeldano AM,et al.Equivalent therapeutic efficacy and safety of ivermectin and lindan in the treatment of human scabies.Arch Dermatol 1999;135:651-655
16. Burkhart CG.Burkhart CN.Burkhart KM.An epidemiologic and therapeutic reassessment of scabies.Cuffs 2000,65(Apr):233-240
17. Gardon J,Gardon-Wendel N,et al.Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa Loa infection. Lancet 1997;350:18-22
18. Barkwell R,Shiels S.Deaths associated with ivermectin treatment of scabies. Lancet 1997;349:1144-1145
19. Giudice PD,Marty P, et al.Ivermetin in elderly patients. Arch Dermatol 1999 Mar;135(13):351-2
20. Hardman JL,Limbird LE.Drugs used in the chemotherapy of helminthiasis. The Pharmacological basis of therapeutics. 1996 9/e 1017-1018
21. Magda Y.M.,Youssee Hayam A.H.,et al.Topical application of ivermeetin for human ectoparasites.Am J Trop Hyg 1995 53(6):652-653
22. Forstinger C.,Kittler H.,and Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream.J Am Acad Dermatol 1999;41(5):775-777